Drug Trial Radar · NCT00953199
Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis
Last checked: Nov 19, 2026Latest source record: Oct 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
506
Actual
Start
Mar 2010
Primary completion
May 2013
Study completion May 2013
Sponsor
- Lead sponsor
- Abraham Mathew MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Milton S. Hershey Medical Center
- First posted
- Aug 6, 2009
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if lidocaine is effective in reducing the incidence of post-ERCP pancreatitis.
Conditions
- Pancreatitis
Interventions
Lidocaine HydrochlorideDrug
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
Normal SalineDrug
1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Post ERCP Pancreatitis is the Primary Outcome.Time frame: 24-48 hours post-procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Penn State College of Medicine, Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.